Abstract
Hypermethylation of the Wnt inhibitory factor-1 (WIF-1) promoter has been implicated in the overactivation of the Wnt pathway in human lung cancer. Curcuminoids exert anti-cancer effects and have been reported to act as hypomethylating agents. Previously, we have investigated and compared the demethylation effects of three curcuminoids and observed that bisdemethoxycurcumin exhibited the strongest demethylation potency. In this study, we used lung cancer cell lines with WIF-1 promoter hypermethylated as a model to study the demethylating effect of bisdemethoxycurcumin on WIF-1 restoration, Wnt signaling activity and cell death. Bisdemethoxycurcumin directly suppressed the activity of DNA methyltransferase-1 (DNMT1) but did not influence DNMT1 expression. In addition, it induced WIF-1 promoter demethylation and protein re-expression. WIF-1 restoration in lung cancer cells down-regulated nuclear β-catenin and the canonical Wnt cascade. Furthermore, we also showed that down-regulation of Wnt signaling by WIF-1 was required for bisdemethoxycurcumin-induced apoptosis in certain lung cancer cell types. This report is the first to show that bisdemethoxycurcumin induces apoptosis by reactivating WIF-1 from a silenced state. Our results provide new insights into the anti-cancer actions of bisdemethoxycurcumin.
Keywords: Apoptosis, bisdemethoxycurcumin, lung neoplasms, promoter demethylation, Wnt inhibitory factor-1, DNA methyltransferase-1, Epidermal growth factor receptor, Non-small-cell lung cancer, TCF response elements, Wingless/int
Current Cancer Drug Targets
Title: The Hypomethylation Agent Bisdemethoxycurcumin Acts on the WIF-1 Promoter, Inhibits the Canonical Wnt Pathway and Induces Apoptosis in Human Non-Small-Cell Lung Cancer
Volume: 11 Issue: 9
Author(s): Y.-L. Liu, H.-P. Yang, X.-D. Zhou, L. Gong, C.-L. Tang and H.-J. Wang
Affiliation:
Keywords: Apoptosis, bisdemethoxycurcumin, lung neoplasms, promoter demethylation, Wnt inhibitory factor-1, DNA methyltransferase-1, Epidermal growth factor receptor, Non-small-cell lung cancer, TCF response elements, Wingless/int
Abstract: Hypermethylation of the Wnt inhibitory factor-1 (WIF-1) promoter has been implicated in the overactivation of the Wnt pathway in human lung cancer. Curcuminoids exert anti-cancer effects and have been reported to act as hypomethylating agents. Previously, we have investigated and compared the demethylation effects of three curcuminoids and observed that bisdemethoxycurcumin exhibited the strongest demethylation potency. In this study, we used lung cancer cell lines with WIF-1 promoter hypermethylated as a model to study the demethylating effect of bisdemethoxycurcumin on WIF-1 restoration, Wnt signaling activity and cell death. Bisdemethoxycurcumin directly suppressed the activity of DNA methyltransferase-1 (DNMT1) but did not influence DNMT1 expression. In addition, it induced WIF-1 promoter demethylation and protein re-expression. WIF-1 restoration in lung cancer cells down-regulated nuclear β-catenin and the canonical Wnt cascade. Furthermore, we also showed that down-regulation of Wnt signaling by WIF-1 was required for bisdemethoxycurcumin-induced apoptosis in certain lung cancer cell types. This report is the first to show that bisdemethoxycurcumin induces apoptosis by reactivating WIF-1 from a silenced state. Our results provide new insights into the anti-cancer actions of bisdemethoxycurcumin.
Export Options
About this article
Cite this article as:
Liu Y.-L., Yang H.-P., Zhou X.-D., Gong L., Tang C.-L. and Wang H.-J., The Hypomethylation Agent Bisdemethoxycurcumin Acts on the WIF-1 Promoter, Inhibits the Canonical Wnt Pathway and Induces Apoptosis in Human Non-Small-Cell Lung Cancer, Current Cancer Drug Targets 2011; 11 (9) . https://dx.doi.org/10.2174/156800911798073041
DOI https://dx.doi.org/10.2174/156800911798073041 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mesenchymal Stem Cells: New Approaches for the Treatment of Neurological Diseases
Current Stem Cell Research & Therapy 5-Fluorouracil Buccal Tablets for Locoregional Chemotherapy of Oral Squamous Cell Carcinoma: Formulation, Drug Release and Histological Effects on Reconstituted Human Oral Epithelium and Porcine Buccal Mucosa
Current Drug Delivery Editorial from Editor-in-Chief: Alternative and Complementary Medicine in Pulmonary Conditions
Current Respiratory Medicine Reviews Electrochemical Indicators for DNA Electroanalysis
Current Analytical Chemistry MicroRNA Dysregulation in the Myelodysplastic Syndromes
MicroRNA Advancements in Adjuvanticity of Bioactive Inorganic and Organic Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets Roles of Tumor Microenvironment in Hepatocelluar Carcinoma
Current Cancer Therapy Reviews Herpesvirus / Retrovirus Chimeric Vectors
Current Gene Therapy Computational Insights for the Discovery of Non-ATP Competitive Inhibitors of MAP Kinases
Current Pharmaceutical Design Antiangiogenesis in Myelodysplastic Syndrome
Current Cancer Drug Targets MATra - Magnet Assisted Transfection: Combining Nanotechnology and Magnetic Forces to Improve Intracellular Delivery of Nucleic Acids
Current Pharmaceutical Biotechnology A “Crazy Paving” Pattern on CT Scan in a Patient Treated with Pembrolizumab
Current Drug Safety A Novel Feature-Significance Based k-Nearest Neighbour Classification Approach for Computer Aided Diagnosis of Lung Disorders
Current Medical Imaging PI3K Pathway Inhibitors: Better Not Left Alone
Current Pharmaceutical Design Polysaccharide-K (PSK) in Cancer - Old Story, New Possibilities?
Current Medicinal Chemistry Synthesis of Novel Coumarin Derivatives 7,8-Fused onto Thiazole
Letters in Organic Chemistry Development of New Drugs for COPD
Current Medicinal Chemistry Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer
Current Cancer Drug Targets Bortezomib: A New Pro-Apoptotic Agent in Cancer Treatment
Current Cancer Drug Targets A Role for SHIP in Stem Cell Biology and Transplantation
Current Stem Cell Research & Therapy